Cargando…
Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial
Esophageal cancer is the sixth most common cancer worldwide. Approximately 50% of patients have locally advanced disease. The CROSS and NEOCRTEC5010 trials have demonstrated that neoadjuvant chemoradiotherapy followed by surgery is the standard treatment for patients with resectable disease. However...
Autores principales: | Lin, Yan, Liang, Huan-Wei, Liu, Yang, Pan, Xin-Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582756/ https://www.ncbi.nlm.nih.gov/pubmed/37860010 http://dx.doi.org/10.3389/fimmu.2023.1264912 |
Ejemplares similares
-
A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577
por: Pape, Marieke, et al.
Publicado: (2022) -
CheckMATE tutorial
por: Kim, Jong Soo, et al.
Publicado: (2021) -
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
por: Ready, Neal, et al.
Publicado: (2018) -
Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
por: Tomita, Yoshihiko, et al.
Publicado: (2017) -
First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
por: Liu, Tianshu, et al.
Publicado: (2022)